Cannabis Clinical Trials

Trial Underway to Provide Scientific Validity of the Analgesic Efficacy and Safety of Medical Cannabis in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model of Multiple Sclerosis (MS)-Induced Neuropathic Pain SASKATOON, Saskatchewan WINNIPEG, Manitoba–(BUSINESS WIRE)–As one of the major symptoms experienced by patients with… read more at: https://www.newcannabisventures.com/cannimed-announces-pre-clinical-research-study-of-cannabis-for-multiple-sclerosis-ms-induced-neuropathic-pain/

by

The first federally approved clinical trial on marijuana as a treatment for post-traumatic stress is now underway. Researchers on Monday began administering marijuana to the first participant of a trial approved by the Drug Enforcement Administration and the Food and Drug Administration, with an intention to create a cannabis-based legal prescription drug, reports Military.com. The […]

by

In a brand new clinical study that has been in the works for more than four years, a U.S. military veteran was given marijuana to study the effects of the drug and its potential role in treating post-traumatic stress disorder (PTSD). The first participant of the study was administered cannabis at the Scottsdale Research Institute in […]

by

On February 6, 2017, the first participant in the first-ever clinical trial of smoked marijuana (cannabis) for posttraumatic stress disorder (PTSD) in U.S. veterans received cannabis at the Scottsdale Research Institute (SRI) in Phoenix, Ariz. This is the first time this investigational drug has been dispensed to a participant in the non-profit Multidisciplinary Association for […]

by

On February 6, 2017, the first participant in the first-ever clinical trial of smoked marijuana (cannabis) for posttraumatic stress disorder (PTSD) in U.S. veterans received cannabis at the Scottsdale Research Institute (SRI) in Phoenix, Ariz. This is the first time this investigational drug has been dispensed to a participant in the non-profit Multidisciplinary Association for […]

by

GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma GW intends to advance oncology research and development efforts LONDON, Feb. 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused… read more at: https://www.newcannabisventures.com/gw-pharma-reports-success-in-brain-cancer-phase-2-clinical-trial/

by

GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma GW intends to advance oncology research and development efforts LONDON, Feb. 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused… read more at: https://www.newcannabisventures.com/gw-pharma-reports-success-in-brain-cancer-phase-2-clinical-trial/

by

The Ministerial Committee for Legislation gave an initial nod on Sunday for the export of medical cannabis in what could be a windfall for companies in Israel, widely regarded as a leader in research in the field. The initiator of the bill, MK Yoav Kisch (Likud), said the approval of his legislation could boost the […]

by

NANAIMO, British Columbia–(BUSINESS WIRE)– Tilray, a global leader in medical cannabis research and production, today announced that it has received necessary regulatory approvals in Canada and Chile to export medical cannabis for distribution to Chilean patients. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170201005120/en/ “Today’s announcement marks Tilray’s entry into Latin […]

by

The Initial Focus Will Be Clinical Studies of the Company’s Prana Product Line DENVER, CO / ACCESSWIRE / January 30, 2017 / United Cannabis Corporation (CNAB) (the “Company” or “United Cannabis”) today announced that it, along with its Jamaica-based subsidiary, Cannabis Research Development (“CRD”), has signed a Letter of Intent (the “LOI”) with the Caribbean […]

by